CervoMed Q3 2020 Earnings Report
Key Takeaways
Diffusion Pharmaceuticals reported financial results for the third quarter of 2020, highlighting a strengthened leadership team, $21.9 million in cash and cash equivalents, and progress in the clinical trial evaluating TSC in COVID-19 patients.
Strengthened leadership team with key management appointments.
Ended quarter with $21.9 million in cash and cash equivalents.
Announced dosing of first patients in Phase 1b clinical trial evaluating TSC in hospitalized COVID-19 patients.
Patient enrollment continues with no dose-limiting toxicities observed as of November 11, 2020.
CervoMed
CervoMed
Forward Guidance
Diffusion Pharmaceuticals expects to fully fund new studies with cash-on-hand, provide additional details regarding the design of these new studies in January 2021, and initiate the studies during the first quarter of 2021. The company also expects the 100-303 COVID Trial to be completed with topline data available by the end of first quarter of 2021.
Positive Outlook
- Fully fund studies with cash-on-hand.
- Provide additional details regarding the design of new studies in January 2021.
- Initiate the studies during the first quarter of 2021.
- Complete the 100-303 COVID Trial.
- Topline data available by the end of first quarter of 2021.